Unlike the many US success stories, there are virtually no European biotech companies breaking into the “Big League” of fully-fledged biopharma companies. In Vivo spoke with the CEO of one exception, Munich-based MorphoSys to provide more insight into Europe’s maturing biopharma marketing. MorphoSys now possesses an impressive pipeline of partnered and in-house molecules. Talking with In Vivo just weeks after taking the helm of the company, Jean-Paul Kress said he is focusing on flawless FDA filing of tafasitamab, establishing a strong commercial base in the US, and sealing a partnership to maximize the drug’s revenues.